Key facts
- Nusano’s last known valuation is $265.0M (Oct 2024).
- It has raised $217.7M across 2 recorded rounds; the latest was Early Stage VC ($10.0M) in Nov 2022.
- Notable investors include S32, Casdin Capital, Verily Life Sciences, Wasatch Equity Partners, ACS BrightEdge — 8 tracked in total.
- Nusano has filed 2 Form Ds with the SEC since 2021, most recently Nov 2022 ($10.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Nusano
Funding rounds
2 roundsAbout Nusano
Developer of a current ion source and linear accelerator intended to remove the current limitations of radioisotope manufacturing for medical applications and innovation. The company offers a broad range of diagnostic and therapeutic radioisotopes, which are produced uranium-free, helping healthcare sector clients develop radiopharmaceuticals for personalized cancer therapies at comparatively lower costs.
- Sector
- Healthcare
- HQ
- Santa Clarita, CA, United States
- Founded
- 2016
- Employees
- 175
- Website
- nusano.com/
- Ownership
- Privately Held (backing)
Nusano doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nusano shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nusano in its N-PORT filings yet. We sweep new filings monthly.